Magazin
2008-04-14
Calgary, Canada (ots/PRNewswire) -
- Natural Hydresia(TM) G2 Offers Enhanced Formulation FlexibilityWith a Globally Accepted Preservative System
Botaneco, a wholly owned subsidiary of SemBioSys Genetics Inc.(TSX: SBS), focused on the development and commercialization ofoleosome technology in personal care, OTC and topical pharmaceuticalmarkets, today announced the launch of its second generationoleosome product, Hydresia(TM ) G2, at the In-Cosmetics 2008exposition in Amsterdam. Hydresia(TM) G2, a natural emulsion base,retains all of the functional performance properties of Botaneco'sfirst generation Hydresia(TM) product, while offering formulatorsthe ability to develop products over a broader pH range (3.5- 8.5).This will allow for the development of low pH exfoliants and anti-aging products that can provide consumers with the moisturization,skin health and aesthetic benefits that Hydresia(TM) brings to otherfinished formulations. In addition, Hydresia(TM) G2 uses a newglobally accepted preservative system that will expand the use ofoleosomes in European and other markets.
"Botaneco is committed to developing ingredients that allow ourcustomers to provide differentiated products that offer bothperformance and aesthetic benefits to consumers," said Andrew Baum,President and CEO of Botaneco's parent company, SemBioSys."Hydresia(TM) G2 can be used in moisturizers, hair and skincleansers, lip care, color cosmetics, skin lighteners, sun care andbaby care products just like our first generation Hydresia(TM)product. In addition to these applications, Hydresia(TM) G2 canalso be used in products where requirements for low pH have precludedthe use of Hydresia(TM). We are excited about the opportunity toexpand our product offerings in North America, as well as expandinginto European and Asian markets."
Hydresia(TM) G2, as well as the first generation Hydresia(TM)product, each allow cosmetic and health care formulators to developnew products using "cold-processing" which reduces formulation andprocessing time by an order of magnitude.
Botaneco's proprietary Hydresia and Hydresia(TM) G2 products arenatural emulsifiers comprised of oleosomes, natural oil carryingstructures derived from safflower seeds. Oleosomes are nature'swarehouse, or storage facility, for the emollient oils, antioxidantsand natural moisture barriers that serve to keep the skin soft,supple and young looking. Using a proprietary non-solvent aqueousextraction process, these oleosomes are isolated from the seed fullyintact, and when used in skin care applications can provide lastingprotection to the skin. Hydresia(TM) and Hydresia(TM) G2 arenatural, renewable replacements for hydrocarbon derived petrolatum,mineral oil and non-ionic surfactants.
About Botaneco
Botaneco is the global developer and marketer of innovativeoleosome- based ingredients to the personal care and OTC topicalmarkets. As a technologically driven provider of high performance,proprietary oleosome based ingredients, Botaneco is committed todeveloping groundbreaking ingredients that offer multifunctional,tangible and documented benefits to both formulators and consumers.Botaneco's manufacturing facility is located in Calgary, Canadawhile its sales and marketing and research and developmentlaboratories are in Bensalem PA.
More information is available and can be accessed athttp://www.botaneco.ca.
About SemBioSys (TSX:SBS)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnologycompany developing protein-based pharmaceuticals for metabolic andcardiovascular diseases. The Company's lead pharmaceuticalcandidates, produced in the plant host safflower, are recombinanthuman insulin, to serve the rapidly expanding global diabetes marketand Apo AI, a next generation cardiovascular drug. In addition to itspharmaceutical products, SemBioSys is developing a series ofnon-pharmaceutical products addressing human topical, nutritionaloils and agricultural biotechnology markets. More information isavailable and can be accessed at http://www.sembiosys.com.
This press release contains certain forward-looking statements,including, without limitation, statements containing the words"believe", "may", "plan", "will", "estimate", "continue","anticipate", "intend", "expect" and other similar expressions whichconstitute "forward-looking information" within the meaning ofapplicable Canadian securities laws. Forward-looking statementsreflect the Company's current expectation and assumptions, and aresubject to a number of risks and uncertainties that could causeactual results to differ materially from those anticipated. Theseforward-looking statements involve risks and uncertainties including,but not limited to, changing market conditions, the successful andtimely completion of clinical studies, the establishment of corporatealliances, the impact of competitive products and pricing, newproduct development, uncertainties related to the regulatory approvalprocess and other risks detailed from time-to-time in the Company'songoing filings with the Canadian securities regulatory authoritieswhich filings can be found at http://www.sedar.com. Given these risksand uncertainties, readers are cautioned not to place undue relianceon such forward-looking statements. The Company undertakes noobligation to publicly update or revise any forward-lookingstatements either as a result of new information, future events orotherwise, except as required by applicable Canadian securities laws.
ots Originaltext: Botaneco and SemBioSys Genetics Inc.Im Internet recherchierbar: http://www.presseportal.de
Contact:Media and Business Contact: Andrew Baum, Botaneco, Ph: +1-403-717-8751, Fax: +1-403-250-3886, Email: bauma@sembiosys.com, Internet: http://www.botaneco.ca
Botaneco Announces Launch of Second Generation Oleosome Product
- Natural Hydresia(TM) G2 Offers Enhanced Formulation FlexibilityWith a Globally Accepted Preservative System
Botaneco, a wholly owned subsidiary of SemBioSys Genetics Inc.(TSX: SBS), focused on the development and commercialization ofoleosome technology in personal care, OTC and topical pharmaceuticalmarkets, today announced the launch of its second generationoleosome product, Hydresia(TM ) G2, at the In-Cosmetics 2008exposition in Amsterdam. Hydresia(TM) G2, a natural emulsion base,retains all of the functional performance properties of Botaneco'sfirst generation Hydresia(TM) product, while offering formulatorsthe ability to develop products over a broader pH range (3.5- 8.5).This will allow for the development of low pH exfoliants and anti-aging products that can provide consumers with the moisturization,skin health and aesthetic benefits that Hydresia(TM) brings to otherfinished formulations. In addition, Hydresia(TM) G2 uses a newglobally accepted preservative system that will expand the use ofoleosomes in European and other markets.
"Botaneco is committed to developing ingredients that allow ourcustomers to provide differentiated products that offer bothperformance and aesthetic benefits to consumers," said Andrew Baum,President and CEO of Botaneco's parent company, SemBioSys."Hydresia(TM) G2 can be used in moisturizers, hair and skincleansers, lip care, color cosmetics, skin lighteners, sun care andbaby care products just like our first generation Hydresia(TM)product. In addition to these applications, Hydresia(TM) G2 canalso be used in products where requirements for low pH have precludedthe use of Hydresia(TM). We are excited about the opportunity toexpand our product offerings in North America, as well as expandinginto European and Asian markets."
Hydresia(TM) G2, as well as the first generation Hydresia(TM)product, each allow cosmetic and health care formulators to developnew products using "cold-processing" which reduces formulation andprocessing time by an order of magnitude.
Botaneco's proprietary Hydresia and Hydresia(TM) G2 products arenatural emulsifiers comprised of oleosomes, natural oil carryingstructures derived from safflower seeds. Oleosomes are nature'swarehouse, or storage facility, for the emollient oils, antioxidantsand natural moisture barriers that serve to keep the skin soft,supple and young looking. Using a proprietary non-solvent aqueousextraction process, these oleosomes are isolated from the seed fullyintact, and when used in skin care applications can provide lastingprotection to the skin. Hydresia(TM) and Hydresia(TM) G2 arenatural, renewable replacements for hydrocarbon derived petrolatum,mineral oil and non-ionic surfactants.
About Botaneco
Botaneco is the global developer and marketer of innovativeoleosome- based ingredients to the personal care and OTC topicalmarkets. As a technologically driven provider of high performance,proprietary oleosome based ingredients, Botaneco is committed todeveloping groundbreaking ingredients that offer multifunctional,tangible and documented benefits to both formulators and consumers.Botaneco's manufacturing facility is located in Calgary, Canadawhile its sales and marketing and research and developmentlaboratories are in Bensalem PA.
More information is available and can be accessed athttp://www.botaneco.ca.
About SemBioSys (TSX:SBS)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnologycompany developing protein-based pharmaceuticals for metabolic andcardiovascular diseases. The Company's lead pharmaceuticalcandidates, produced in the plant host safflower, are recombinanthuman insulin, to serve the rapidly expanding global diabetes marketand Apo AI, a next generation cardiovascular drug. In addition to itspharmaceutical products, SemBioSys is developing a series ofnon-pharmaceutical products addressing human topical, nutritionaloils and agricultural biotechnology markets. More information isavailable and can be accessed at http://www.sembiosys.com.
This press release contains certain forward-looking statements,including, without limitation, statements containing the words"believe", "may", "plan", "will", "estimate", "continue","anticipate", "intend", "expect" and other similar expressions whichconstitute "forward-looking information" within the meaning ofapplicable Canadian securities laws. Forward-looking statementsreflect the Company's current expectation and assumptions, and aresubject to a number of risks and uncertainties that could causeactual results to differ materially from those anticipated. Theseforward-looking statements involve risks and uncertainties including,but not limited to, changing market conditions, the successful andtimely completion of clinical studies, the establishment of corporatealliances, the impact of competitive products and pricing, newproduct development, uncertainties related to the regulatory approvalprocess and other risks detailed from time-to-time in the Company'songoing filings with the Canadian securities regulatory authoritieswhich filings can be found at http://www.sedar.com. Given these risksand uncertainties, readers are cautioned not to place undue relianceon such forward-looking statements. The Company undertakes noobligation to publicly update or revise any forward-lookingstatements either as a result of new information, future events orotherwise, except as required by applicable Canadian securities laws.
ots Originaltext: Botaneco and SemBioSys Genetics Inc.Im Internet recherchierbar: http://www.presseportal.de
Contact:Media and Business Contact: Andrew Baum, Botaneco, Ph: +1-403-717-8751, Fax: +1-403-250-3886, Email: bauma@sembiosys.com, Internet: http://www.botaneco.ca
Botaneco and SemBioSys Genetics Inc.
| Preisvergleich Medikamente |
|
In Zusammenarbeit mit Medizinfuchs |
